234 related articles for article (PubMed ID: 24512488)
1. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
Cui B; Yang Q; Guan H; Shi B; Hou P; Ji M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E962-70. PubMed ID: 24512488
[TBL] [Abstract][Full Text] [Related]
2. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
3. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.
Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P
J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545
[TBL] [Abstract][Full Text] [Related]
4. PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation.
Furukawa H; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Cancer Sci; 2018 Feb; 109(2):412-421. PubMed ID: 29168598
[TBL] [Abstract][Full Text] [Related]
5. Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis.
Cory AH; Chen J; Cory JG
Anticancer Res; 2006; 26(2A):1289-95. PubMed ID: 16619536
[TBL] [Abstract][Full Text] [Related]
6. PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Izetti P; Hautefeuille A; Abujamra AL; de Farias CB; Giacomazzi J; Alemar B; Lenz G; Roesler R; Schwartsmann G; Osvaldt AB; Hainaut P; Ashton-Prolla P
Invest New Drugs; 2014 Oct; 32(5):783-94. PubMed ID: 24838627
[TBL] [Abstract][Full Text] [Related]
7. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
Ramraj SK; Elayapillai SP; Pelikan RC; Zhao YD; Isingizwe ZR; Kennedy AL; Lightfoot SA; Benbrook DM
Int J Cancer; 2020 Aug; 147(4):1086-1097. PubMed ID: 31845320
[TBL] [Abstract][Full Text] [Related]
8. Hypoxic resistance of KRAS mutant tumor cells to 3-Bromopyruvate is counteracted by Prima-1 and reversed by N-acetylcysteine.
Orue A; Chavez V; Strasberg-Rieber M; Rieber M
BMC Cancer; 2016 Nov; 16(1):902. PubMed ID: 27863474
[TBL] [Abstract][Full Text] [Related]
9. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
Liang Y; Besch-Williford C; Hyder SM
Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
[TBL] [Abstract][Full Text] [Related]
10. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249.
Shi H; Lambert JM; Hautefeuille A; Bykov VJ; Wiman KG; Hainaut P; Caron de Fromentel C
Carcinogenesis; 2008 Jul; 29(7):1428-34. PubMed ID: 18048389
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Avan A; Crea F; Paolicchi E; Funel N; Galvani E; Marquez VE; Honeywell RJ; Danesi R; Peters GJ; Giovannetti E
Mol Cancer Ther; 2012 Aug; 11(8):1735-46. PubMed ID: 22622284
[TBL] [Abstract][Full Text] [Related]
13. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study.
Benakanakere I; Besch-Williford C; Ellersieck MR; Hyder SM
Endocr Relat Cancer; 2009 Mar; 16(1):85-98. PubMed ID: 19075036
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
15. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
[TBL] [Abstract][Full Text] [Related]
16. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells.
Liang Y; Besch-Williford C; Benakanakere I; Hyder SM
Int J Oncol; 2007 Oct; 31(4):777-84. PubMed ID: 17786308
[TBL] [Abstract][Full Text] [Related]
17. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway.
Li Y; Mao Y; Brandt-Rauf PW; Williams AC; Fine RL
Mol Cancer Ther; 2005 Jun; 4(6):901-9. PubMed ID: 15956247
[TBL] [Abstract][Full Text] [Related]
18. Antitumor Effects of PRIMA-1 and PRIMA-1
Menichini P; Monti P; Speciale A; Cutrona G; Matis S; Fais F; Taiana E; Neri A; Bomben R; Gentile M; Gattei V; Ferrarini M; Morabito F; Fronza G
Cells; 2021 Jan; 10(1):. PubMed ID: 33430525
[TBL] [Abstract][Full Text] [Related]
19. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.
Liang Y; Besch-Williford C; Benakanakere I; Thorpe PE; Hyder SM
Breast Cancer Res Treat; 2011 Jan; 125(2):407-20. PubMed ID: 20349129
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines.
Unland R; Borchardt C; Clemens D; Kool M; Dirksen U; Frühwald MC
Anticancer Drugs; 2015 Mar; 26(3):301-11. PubMed ID: 25415657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
